Drug Trial Radar · NCT02374567
Pharmacovigilance in Gerontopsychiatric Patients
Last checked: Nov 19, 2026Latest source record: Feb 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
407
Actual
Start
Jan 2015
Primary completion
Jun 28, 2017
Study completion Jun 28, 2017
Sponsor
- Lead sponsor
- Hannover Medical SchoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment. The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises. To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites. At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed. Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system. In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually. 2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.
Conditions
- Dementia
- Depression
- Schizophrenia
- Psychosomatic Disorders
- Anxiety Disorders
Interventions
PhenobarbitalDrug
PhenytoinDrug
CarbamazepineDrug
OxcarbazepineDrug
Valproic AcidDrug
LamotrigineDrug
TopiramateDrug
GabapentinDrug
LevetiracetamDrug
PregabalinDrug
LacosamideDrug
ClonazepamDrug
BiperidenDrug
LevomepromazineDrug
FluphenazineDrug
PerphenazineDrug
PerazineDrug
ThioridazineDrug
HaloperidolDrug
MelperoneDrug
PipamperoneDrug
BromperidolDrug
BenperidolDrug
SertindoleDrug
ZiprasidoneDrug
FlupentixolDrug
ChlorprothixeneDrug
ZuclopenthixolDrug
FluspirileneDrug
PimozideDrug
ClozapineDrug
OlanzapineDrug
QuetiapineDrug
SulpirideDrug
TiaprideDrug
AmisulprideDrug
ProthipendylDrug
RisperidoneDrug
AripiprazoleDrug
PaliperidoneDrug
DiazepamDrug
OxazepamDrug
LorazepamDrug
BromazepamDrug
ClobazamDrug
AlprazolamDrug
HydroxyzineDrug
BuspironeDrug
Chloral HydrateDrug
FlurazepamDrug
NitrazepamDrug
TriazolamDrug
LormetazepamDrug
TemazepamDrug
MidazolamDrug
BrotizolamDrug
ZopicloneDrug
ZolpidemDrug
ZaleplonDrug
MelatoninDrug
ClomethiazoleDrug
DiphenhydramineDrug
PromethazineDrug
ImipramineDrug
ClomipramineDrug
OpipramolDrug
TrimipramineDrug
AmitriptylineDrug
NortriptylineDrug
DoxepinDrug
MaprotilineDrug
Amitriptyline oxideDrug
FluoxetineDrug
CitalopramDrug
ParoxetineDrug
SertralineDrug
FluvoxamineDrug
EscitalopramDrug
TranylcypromineDrug
MoclobemideDrug
MianserinDrug
TrazodoneDrug
MirtazapineDrug
BupropionDrug
VenlafaxineDrug
ReboxetineDrug
DuloxetineDrug
AgomelatineDrug
PyritinolDrug
PiracetamDrug
DonepezilDrug
RivastigmineDrug
GalantamineDrug
MemantineDrug
NicergolineDrug
AcamprosateDrug
LithiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of frequency and severity of adverse eventsTime frame: Participants will be followed for the duration of hospital stay and the follow-up-visit, an expected average of 6 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Bezirkskrankenhaus Augsburg
Augsburg, Germany
Krankenhaus Hedwigshöhe
Berlin, Germany
Hannover Medical School
Hanover, Germany
Asklepios Fachklinikum Lübben
Lubin, Germany
Asklepios Fachklinikum Teupitz
Teupitz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.